Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia.

Abstract

BACKGROUND/AIM:

Seminal plasma cfDNA (scfDNA) was recently proposed as a novel PCa biomarker. Our aim was to evaluate whether scfDNA could discriminate PCa from benign prostate hyperplasia (BPH) patients.

PATIENTS AND METHODS:

A cohort of 43 patients (18 and 25 pathology proven PCa and BPH patients), and 13 healthy age-matched control subjects were enrolled. scfDNA quantification was performed. Data were analyzed through ANOVA testing.

RESULTS:

Average scfDNA concentrations were 1,407.83 ng/μl, 128.13 ng/μl and 78.09 ng/μl for PCa patients, BPH patients and healthy subjects, respectively. Statistical analysis showed a significant difference among the groups, allowing for distinction of patients with optimal accuracy. A cut-off level of 450 ng/μl scfDNA was identified for the differentiation of PCa and BPH patients.

CONCLUSION:

scfDNA concentrations are significantly different between PCa patients and BPH patients. scfDNA is a promising biomarker with several applications in PCa diagnosis, screening programs and therapeutic monitoring.

• Authors: Giovanni Ponti, Monia Maccaferri, Salvatore Micali, Marco Manfredini, Riccardo Milandri, Giampaolo Bianchi, Giovanni Pellacani, Shaniko Kaleci, Johanna Chester, Andrea Conti, Chiara Del Prete, Aldo Tomasi
• Journal: Anticancer research (Anticancer Res) Vol. 38 Issue 9 Pg. 5121-5125 (Sep 2018) ISSN: 1791-7530 [Electronic] Greece
• PMID: 30194158 (Publication Type: Journal Article)
• Copyright: Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Cell-Free Nucleic Acids

Topics

• Aged
• Cell-Free Nucleic Acids (analysis)
• Cohort Studies
• Diagnosis, Differential
• Humans
• Male
• Middle Aged
• Prostatic Hyperplasia (diagnosis, genetics)
• Prostatic Neoplasms (diagnosis, genetics)